Quick Facts: Procare

• Therapeutic Domain: Used to address certain eye surface conditions, including keratitis and corneal defects.
• Function: Intended to support the healing process of damaged ocular surfaces.
• Primary Use: Management of specific ocular surface diseases associated with inflammation.

---

What Procare Treats: Main Uses and Benefits

Procare (also referred to by the specific device name Prokera in clinical contexts) is a medical device intended for use by eye care professionals. Its primary therapeutic purpose is to support the resolution of ocular surface diseases that involve inflammation and damage to the cornea.

Clinical use is focused on specific conditions such as keratitis (inflammation of the cornea), corneal defects, and partial limbal stem cell deficiency. It is employed to manage and mitigate the processes of inflammation and scarring on the eye's surface.

The therapeutic function of this device is to create an environment that facilitates the natural healing process of the damaged ocular surface. When applied, the device provides a protective layer and is utilized to promote a return to a healthy corneal state.

Regulatory References

1. https://www.accessdata.fda.gov/cdrhdocs/pdf16/K162917.pdf

Who Can and Cannot Use Procare (Propofol)

The official eligibility profile for Procare, whose active ingredient is Propofol, is defined by absolute contraindications and population-specific restrictions documented in regulatory labeling. The medicine's use is strictly limited to controlled medical settings.

Classification	Population Eligibility / Restriction
Absolute Contraindication	Patients with a known hypersensitivity to Propofol or any component of its formulation, including those with documented egg or soy product allergies [FDA Label].
Pediatric Restriction	Contraindicated for Intensive Care Unit (ICU) sedation in patients 16 years of age or younger. Approved for general anesthesia maintenance in children ge 2 months, and induction in children ge 3 years of age [FDA Label].
Pregnancy/Lactation	Not recommended for routine obstetric anesthesia (e.g., Cesarean section). Use during pregnancy is conditional on the benefit outweighing the potential fetal risk. Use during breastfeeding is not recommended by some manufacturers [FDA Label, LactMed].
Conditional Use	Use requires caution and reduced doses in older adults, severely debilitated patients, and those with severe cardiovascular, respiratory, or lipid metabolism disorders [EMA SmPC].

These constraints ensure the drug is administered only to patient groups where its risk profile is established and manageable, according to government-approved prescribing information.

Interactions with other medicines and products for Procare are strictly documented by regulatory authorities. The use of Procare is formally contraindicated in individuals with known hypersensitivity to the drug's components, including egg products or soybean products used in the injectable lipid emulsion.

A major interaction domain is pharmacodynamic synergism with other Central Nervous System (CNS) depressants, such as opioids and benzodiazepines. Co-administration with these agents or with alcohol leads to an additive effect, increasing the risk of pronounced cardiorespiratory depression and hypotension, as officially noted in the prescribing information.

Specific drugs may interfere with Propofol's plasma levels. For example, Apalutamide is documented to decrease Propofol exposure via CYP2C9 enzyme induction, while Abametapir is explicitly noted to increase Propofol serum concentration. Furthermore, certain populations, including the elderly or debilitated patients, exhibit reduced clearance, resulting in higher peak plasma concentrations that magnify the risk of cardiorespiratory interactions.

Procedural constraints govern physical incompatibilities. Intravenous lines used for Procare must be flushed prior to administering Neuromuscular Blocking Agents. Additionally, co-administration with other IV fluids requires careful placement close to the cannula site.

The active ingredient in Procare exerts its mechanism of action by selectively targeting and altering key inhibitory and excitatory signaling pathways within the central nervous system.

Mechanism of Central Inhibition Enhancement

The drug's primary action is centered on the GABA A receptor, which mediates the brain’s main inhibitory neurotransmitter system. The active ingredient binds to this receptor as a positive allosteric modulator, increasing the receptor’s response to GABA. This interaction enhances the influx of chloride ions ( Cl^-) into the neuron, leading to neuronal hyperpolarization. This cellular state suppresses neuronal activity and function across the brain.

Influence on Systemic Vascular Tone

A secondary mechanistic action involves influencing pathways that govern the autonomic nervous system output. The mechanism suppresses sympathetic vasoconstrictor signaling centrally, altering the transmission of signals that typically maintain blood vessel constriction. This action results in the adjustment of processes driven by these signaling patterns and leads to peripheral vasodilation, which subsequently reduces blood pressure and systemic vascular resistance.

Procare (propofol) is an injectable emulsion administered exclusively via the intravenous (IV) route and must only be used in specialized medical settings where continuous patient monitoring and resuscitation equipment are immediately available.

Official Dosing and Titration

Administration is governed by precise, weight-based dosage ranges (mg/kg or mcg/kg/min), requiring strict titration to the individual patient’s clinical response. For induction of general anesthesia, the typical starting dose in a healthy adult is 1.5 mg/kg to 2.5 mg/kg, administered in slow, fractional increments. Maintenance is typically achieved through a continuous variable rate infusion. A mandatory interval of 3 to 5 minutes must be observed between any adjustment in the infusion rate or subsequent bolus injection to fully assess the effect.

Preparation and Time Constraints

Procare is supplied as a 10 mg/mL emulsion. If required, dilution is strictly limited to 5% Dextrose Injection, USP, and the final concentration must not be less than 2 mg/mL. Strict aseptic technique is mandatory for all handling. A critical procedural restriction dictates that the administration must be completed and the product discarded within 12 hours of opening or spiking the vial, regardless of any remaining volume.

Special Population Rules

Dosing must be adapted for patient vulnerability. Older, debilitated, or severely ill patients require a reduced starting dose and slower infusion rates compared to healthy adults. For pediatric patients, the maintenance of sedation is approved for those ≥ 2 months of age, while induction is approved for patients ≥ 3 years of age. For long-term use in the Intensive Care Unit (ICU), the continuous infusion must be titrated daily to the minimum effective rate.

Research evidence / Overview of studies for Procare

Evidence for Use in General Anesthesia and Surgical Procedures

A substantial body of research, including numerous clinical trials, has been used to evaluate Propofol for general anesthesia in surgical patients. Studies monitored key outcomes related to the induction and maintenance of a non-responsive state. Outcomes related to systemic or functional imbalance were evaluated, including the time required for patients to achieve unconsciousness and how quickly patients recovered, measured by the time to extubation or the time to follow verbal commands.

The findings derived from these settings with varying symptom burdens describe patterns observed in the studies, namely measurements of the time required to achieve the anesthetic effect. Research highlights changes measured during the study period, showing shorter recovery times compared to some other agents that were evaluated in the trials.

Evidence for Use in Procedural Sedation

Propofol was also evaluated in research contexts involving fluctuating or unstable symptoms, specifically as a method for procedural sedation. Research examined this use primarily through randomized controlled trials (RCTs) and comparative trials. The outcomes monitored included the rate of successfully achieving the required level of sedation and the time it took until patients could be safely discharged.

Research highlights the time required for the onset of sedation and the ability to adjust the level of sedation through continuous monitoring. Outcomes reported in the studies monitored indicate the measured recovery and discharge times compared to specific longer-acting agents used in the same trials.

Research Gaps and Areas of Uncertainty

While the body of evidence concerning immediate characteristics is extensive, certain areas still remain uncertain. Long-term effects are not fully established regarding potential neurocognitive outcomes following general anesthesia. Furthermore, data for certain groups, such as children requiring continuous infusion over extended periods in intensive care units (ICU), remains insufficient.

Key Studies & References

1. Propofol: Uses, Interactions, Mechanism of Action | DrugBank Online (General Overview)
2. The Incidence of Adverse Events in Adults Undergoing Procedural Sedation with Propofol Administered by Non-Anesthetists: A Systematic Review and Meta-Analysis (Evidence for Procedural Sedation Profile)
3. Continuous propofol perfusion in critically ill children (Source for pediatric ICU limitations)

Common questions about Procare (FAQ)

---

Q: What is the difference between Procare and its generic version?

Procare is the brand name used for the medicine whose active ingredient is Propofol. The generic version contains the same active substance, Propofol. Official documents note that generic products may differ slightly in inactive ingredients, preservatives, or specific formulation details depending on the manufacturer.

---

Q: Can Procare be taken with common prescription medications for blood pressure?

The official product information indicates that Propofol can lead to a decrease in blood pressure, known as hypotension. Therefore, co-administration with other medicines that also lower blood pressure, such as certain antihypertensives, may increase the potential for this effect. It is necessary that the clinical team managing the procedure is aware of all concurrent medications.

---

Q: Is Procare designed for long-term use, or is it a short-course treatment?

Propofol is primarily approved for short-term uses, such as inducing and maintaining general anesthesia during a procedure. While it is used for continuous, longer-term sedation in the Intensive Care Unit (ICU), this administration must be closely controlled. When used in the ICU, the infusion rate is subject to frequent and careful titration by medical staff, and the total duration of use may be restricted.

---

Q: Is Procare considered a 'high-risk' medication in official safety classifications?

Official regulatory documents do not commonly use the specific term 'high-risk,' but they emphasize strict safety requirements for administration. The medication is required to be used only in clinical settings with continuous patient monitoring, immediate availability of resuscitation equipment, and medical personnel specially trained in airway management, reflecting the potential for severe cardiorespiratory depression.

---

Q: Do official documents mention any required special monitoring or lab tests while using Procare?

Yes, continuous patient monitoring of vital signs is a required feature of administration. For patients receiving prolonged, high-dose infusions, especially in the ICU, official product information indicates a need for regular monitoring. This may include checking serum triglycerides, as well as acid-base balance and kidney or liver function tests due to the risk of a rare but serious condition called Propofol Infusion Syndrome (PRIS).

---

Q: Can Procare affect the results of routine medical or laboratory tests?

Propofol is formulated within a lipid emulsion (a fat-based liquid), which can influence certain blood tests. This can lead to increased serum triglyceride levels and may interfere with laboratory measurements of lipids, particularly during long-term infusions. Serious adverse reactions can also cause changes in blood gas and kidney function tests.

---

Q: Can I take Procare at the same time as over-the-counter pain relievers like ibuprofen?

It is necessary that the medical team overseeing the procedure is informed of all medications and supplements you are taking. Official product information notes that Propofol's sedative and cardiovascular effects can be increased by other agents. Decisions regarding concurrent use of any medications are assessed by the administering healthcare professional.

---

Q: Does Procare have a potential for dependence or withdrawal symptoms?

Official documents contain reports suggesting that Propofol may have a potential for abuse when misused. In patients who receive prolonged deep sedation, the rapid discontinuation of the medicine can lead to withdrawal symptoms, which may include agitation, anxiety, and physical discomfort.

---

Q: Why do some people report feeling tired when taking Procare?

The medicine's intended effect is to cause deep sedation by acting as a powerful central nervous system (CNS) depressant. While in recovery, patients may experience residual effects, such as confusion, dizziness, or unusual tiredness and weakness. These symptoms are characteristic of potent sedative agents.

---

Q: Is it normal to experience a change in appetite while on Procare?

Some official safety summaries list loss of appetite as a rare adverse reaction. Separately, the drug's formulation contains fats (lipids). This is a factor that is considered by the clinical team in the patient’s overall nutritional and caloric intake, especially during prolonged use.

---

Q: Has Procare been studied for conditions other than its main indication?

The official FDA label and prescribing information only detail the evidence and clinical trials that support the drug’s approved indications: general anesthesia, procedural sedation, and ICU sedation. Information regarding studies for uses that are not approved or supported by the official label is not included in the prescribing information.

---

Q: Can Procare affect my ability to drive or operate machinery?

Yes, due to its powerful sedative effects, regulatory documents specify that patients are restricted from driving, operating heavy machinery, or engaging in any activity that requires full mental alertness for a specified period after receiving Propofol. This recovery period is typically advised to last 24 hours, even if a person feels fully awake sooner.

Storage and Disposal Requirements

Procare (Propofol Injectable Emulsion) must be stored at a controlled temperature, not above 25 C (77 F), and kept in its original carton to protect it from light. It is strictly forbidden to freeze the emulsion, and any frozen product must be discarded immediately. The medication must be kept out of the reach of children.

Due to its formulation, strict aseptic technique is mandatory during preparation. Once the container is opened, the administration system, including the vial and tubing, must be discarded after a maximum of 12 hours to prevent microbial contamination. Any remaining or expired product must be disposed of in accordance with local pharmaceutical waste requirements and should not be discarded into wastewater.